StockNews.com cut shares of InfuSystem (NYSE:INFU - Free Report) from a strong-buy rating to a buy rating in a research report report published on Thursday.
InfuSystem Price Performance
Shares of NYSE:INFU traded down $0.47 during trading on Thursday, reaching $5.64. The company had a trading volume of 351,153 shares, compared to its average volume of 112,959. The company has a fifty day moving average of $7.92 and a two-hundred day moving average of $7.59. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $119.93 million, a P/E ratio of 94.02 and a beta of 1.75. InfuSystem has a 12 month low of $5.28 and a 12 month high of $9.97.
Hedge Funds Weigh In On InfuSystem
A number of hedge funds and other institutional investors have recently modified their holdings of INFU. GSA Capital Partners LLP lifted its position in InfuSystem by 23.9% in the 3rd quarter. GSA Capital Partners LLP now owns 65,680 shares of the company's stock worth $440,000 after buying an additional 12,657 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in shares of InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company's stock worth $223,000 after acquiring an additional 7,295 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of InfuSystem in the 3rd quarter valued at $87,000. BNP Paribas Financial Markets grew its holdings in shares of InfuSystem by 66.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company's stock valued at $27,000 after purchasing an additional 1,626 shares during the last quarter. Finally, State Street Corp raised its position in InfuSystem by 1.1% in the 3rd quarter. State Street Corp now owns 267,012 shares of the company's stock worth $1,789,000 after purchasing an additional 3,019 shares during the period. 71.13% of the stock is currently owned by hedge funds and other institutional investors.
About InfuSystem
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Read More
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
